Completed PHASE3 INTERVENTIONAL 2-arm NCT01311960

Topical Bevacizumab for Preventing Recurrent Pterygium

Topical Bevacizumab 0.05% Eye Drops for Preventing Recurrent Pterygium, A Randomized, Double-masked, Controlled Trial

Sponsor: Chulalongkorn University

Conditions Anti-VEGF Bevacizumab Pterygium VEGF

Interventions bevacizumab eye drop 0.05% normal saline 0.9%

Updated 5 times since 2017 Last updated: Apr 6, 2013 Started: Dec 31, 2010 Primary completion: Mar 31, 2013 Completion: Apr 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Anti-VEGF and Bevacizumab and is currently completed. Chulalongkorn University leads this study, which shows 5 recorded versions since 2010 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Dec 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chulalongkorn University

Data source: Chulalongkorn University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Pathumwan, Thailand